32.96
price up icon2.67%   0.81
 
loading

Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten

pulisher
06:25 AM

What indicators show strength in Vaxcyte Inc.July 2025 Patterns & Consistent Profit Alerts - Newser

06:25 AM
pulisher
02:14 AM

How to forecast Vaxcyte Inc. trends using time seriesJuly 2025 Summary & Daily Price Action Insights - Newser

02:14 AM
pulisher
02:08 AM

Vaxcyte Inc. stock outlook for YEAROptions Play & Reliable Entry Point Trade Alerts - Newser

02:08 AM
pulisher
01:47 AM

Multi factor analysis applied to Vaxcyte Inc.2025 Earnings Impact & Weekly Market Pulse Updates - Newser

01:47 AM
pulisher
Sep 04, 2025

Vaxcyte Inc. stock trend forecastQuarterly Performance Summary & Precise Swing Trade Alerts - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

How to interpret RSI for Vaxcyte Inc. stockJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Live market analysis of Vaxcyte Inc.Weekly Profit Report & Safe Entry Point Identification - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Is Vaxcyte Inc. forming a reversal patternJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser

Sep 04, 2025
pulisher
Sep 03, 2025

Visualizing Vaxcyte Inc. stock with heatmapsEarnings Miss & Advanced Swing Trade Entry Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Analyzing Vaxcyte Inc. with risk reward ratio charts2025 Support & Resistance & Safe Swing Trade Setups - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Vaxcyte shares rise 1.90% after-hours as VAX-31 Phase 2 study advances to final stage. - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Vaxcyte Says VAX-31 Pneumococcal Disease Study Advances to Final Stage - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

Vaxcyte advances VAX-31 pneumococcal vaccine to final stage of infant study - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal Disease - Quiver Quantitative

Sep 03, 2025
pulisher
Sep 03, 2025

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose - GlobeNewswire

Sep 03, 2025
pulisher
Sep 03, 2025

92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants - Stock Titan

Sep 03, 2025
pulisher
Sep 03, 2025

What recovery options are there for Vaxcyte Inc.2025 Top Gainers & High Conviction Investment Ideas - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

How to build a custom watchlist for Vaxcyte Inc.July 2025 Update & Community Supported Trade Ideas - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will Vaxcyte Inc. stock recover after earningsPortfolio Performance Summary & AI Enhanced Trading Alerts - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

Evaluating Vaxcyte Inc. with trendline analysisWeekly Profit Summary & Long Hold Capital Preservation Tips - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

How institutional ownership impacts Vaxcyte Inc. stockMarket Sentiment Report & Verified Swing Trading Watchlist - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

What is the target price for Vaxcyte Inc. stock2025 Trading Volume Trends & Trade Opportunity Analysis Reports - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

Short interest data insights for Vaxcyte Inc.Volume Spike & Reliable Entry Point Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

How to manage a losing position in Vaxcyte Inc.July 2025 Price Swings & AI Based Buy and Sell Signals - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

Is Vaxcyte Inc. forming a bottoming baseVolume Spike & Technical Confirmation Trade Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Is Vaxcyte Inc. stock good for income investorsWeekly Earnings Recap & Weekly Momentum Picks - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Market Wrap: Can Vaxcyte Inc. expand its profit marginsPortfolio Risk Report & Reliable Trade Execution Plans - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Is Vaxcyte Inc. in a bullish channelQuarterly Portfolio Review & Safe Capital Growth Tips - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Is Vaxcyte Inc. stock reversal real or fakeTrade Analysis Summary & Weekly Market Pulse Updates - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Insider Sell: What is the PEG ratio of Vaxcyte Inc.July 2025 Spike Watch & Consistent Return Investment Signals - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

What is the long term forecast for Vaxcyte Inc. stock2025 Sector Review & Growth Focused Investment Plans - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Risk vs reward if holding onto Vaxcyte Inc.Portfolio Growth Summary & Long-Term Investment Growth Plans - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

InvestingPro’s Fair Value model predicted Vaxcyte’s 46% decline By Investing.com - Investing.com

Sep 02, 2025
pulisher
Sep 02, 2025

Full technical analysis of Vaxcyte Inc. stockTrade Risk Summary & Reliable Entry Point Trade Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

What are Vaxcyte Inc.’s recent SEC filings showingPortfolio Gains Summary & Capital Protection Trade Alerts - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Market Outlook: How does Vaxcyte Inc. compare to its peersQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - khodrobank.com

Sep 02, 2025
pulisher
Sep 01, 2025

Momentum Shift: What are Vaxcyte Inc.’s recent SEC filings showing2025 Big Picture & Low Drawdown Trading Strategies - khodrobank.com

Sep 01, 2025
pulisher
Sep 01, 2025

Is Vaxcyte Inc. vulnerable to short sellersTrade Volume Summary & Low Drawdown Investment Strategies - khodrobank.com

Sep 01, 2025
pulisher
Sep 01, 2025

Advanced analytics toolkit walkthrough for Vaxcyte Inc.2025 Bull vs Bear & Comprehensive Market Scan Reports - Newser

Sep 01, 2025
pulisher
Aug 31, 2025

Can Vaxcyte Inc. Regain Lost Ground This Quarter getLinesFromResByArray error: size == 0 - kangso.co.kr

Aug 31, 2025
$85.73
price up icon 0.23%
$27.52
price up icon 0.55%
$24.41
price up icon 3.64%
$110.50
price up icon 7.16%
$142.47
price down icon 0.21%
biotechnology ONC
$338.36
price up icon 6.16%
Kapitalisierung:     |  Volumen (24h):